Literature DB >> 16331280

Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma.

I Melzner, M A Weniger, C K Menz, P Möller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16331280     DOI： 10.1038/sj.leu.2404036

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders.

Authors:  S E Langabeer; F Ni Ainle; E Conneally; M Lawler
Journal:  Ir J Med Sci       Date:  2007-04-18       Impact factor: 1.568

Review 2.  Beyond chemotherapy: new agents for targeted treatment of lymphoma.

Authors:  Anas Younes
Journal:  Nat Rev Clin Oncol       Date:  2010-12-14       Impact factor: 66.675

3.  Cooperative epigenetic modulation by cancer amplicon genes.

Authors:  Lixin Rui; N C Tolga Emre; Michael J Kruhlak; Hye-Jung Chung; Christian Steidl; Graham Slack; George W Wright; Georg Lenz; Vu N Ngo; Arthur L Shaffer; Weihong Xu; Hong Zhao; Yandan Yang; Laurence Lamy; R Eric Davis; Wenming Xiao; John Powell; David Maloney; Craig J Thomas; Peter Möller; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Kerry Savage; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Dennis D Weisenburger; Wing C Chan; Randy D Gascoyne; David Levens; Louis M Staudt
Journal:  Cancer Cell       Date:  2010-12-14       Impact factor: 31.743

4.  Lack of JAK2 activating non-synonymous mutations in diffuse large B-cell tumors: JAK2 deregulation still unexplained.

Authors:  Thomas E Witzig; Tammy L Price-Troska; Mary J Stenson; Mamta Gupta
Journal:  Leuk Lymphoma       Date:  2012-08-17

Review 5.  Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria.

Authors:  Martha Wadleigh; Ayalew Tefferi
Journal:  Int J Hematol       Date:  2010-02-27       Impact factor: 2.490

6.  Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation.

Authors:  Mamta Gupta; Jing Jing Han; Mary Stenson; Matthew Maurer; Linda Wellik; Guangzhen Hu; Steve Ziesmer; Ahmet Dogan; Thomas E Witzig
Journal:  Blood       Date:  2012-02-08       Impact factor: 22.113

7.  No evidence for the JAK2 (V617F) or JAK2 exon 12 mutations in primary mediastinal large B-cell lymphoma.

Authors:  David Wu; Bethany Dutra; Neal Lindeman; Hidenobu Takahashi; Kunihiko Takeyama; Nancy L Harris; Geraldine S Pinkus; Janina Longtine; Margaret Shipp; Jeffery L Kutok
Journal:  Diagn Mol Pathol       Date:  2009-09

8.  Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo.

Authors:  Yansheng Hao; Bjoern Chapuy; Stefano Monti; Heather H Sun; Scott J Rodig; Margaret A Shipp
Journal:  Clin Cancer Res       Date:  2014-03-07       Impact factor: 12.531

Review 9.  Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.

Authors:  A Tefferi
Journal:  Leukemia       Date:  2010-04-29       Impact factor: 11.528

10.  HSP90 is essential for Jak-STAT signaling in classical Hodgkin lymphoma cells.

Authors:  Nils Schoof; Frederike von Bonin; Lorenz Trümper; Dieter Kube
Journal:  Cell Commun Signal       Date:  2009-07-16       Impact factor: 5.712
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.